2014
DOI: 10.1016/j.tim.2014.04.007
|View full text |Cite
|
Sign up to set email alerts
|

Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

14
580
4
17

Year Published

2015
2015
2024
2024

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 754 publications
(615 citation statements)
references
References 83 publications
14
580
4
17
Order By: Relevance
“…Instead, our result suggests that resistance to tigecycline is not so uncommon and could be a new threat in the therapy of infections. Diffuse resistance to fluoroquinolones was detected: this result seems to be related to their large employment in human and veterinary medicine due to their effectiveness against both Gram-positive and Gram-negative bacteria [21].…”
Section: Discussionmentioning
confidence: 98%
“…Instead, our result suggests that resistance to tigecycline is not so uncommon and could be a new threat in the therapy of infections. Diffuse resistance to fluoroquinolones was detected: this result seems to be related to their large employment in human and veterinary medicine due to their effectiveness against both Gram-positive and Gram-negative bacteria [21].…”
Section: Discussionmentioning
confidence: 98%
“…The high occurrence of pneumococcal antibiotic resistance genes coupled with the ease of horizontal gene transfer have enhanced global dissemination of pneumococcal multi-drug resistance, which has significant impacts on clinical practice. Treatment guidelines for pneumococcal infections must be updated according to the changes in resistance patterns [30,31].…”
Section: Discussionmentioning
confidence: 99%
“…Incluso con las guías actuales, cuyo objetivo es preservar la eficacia de los antimicrobianos, la resistencia a quinolonas sigue ocurriendo en rangos que se incrementa en numerosas especies bacterianas y su uso varía alrededor del mundo. Grecia es el mayor usuario de quinolonas y tiene la mayor incidencia de aislados de Escherichia coli resistente a quinolonas, mientras que Suecia tiene la menor tasa de consumo y la menor incidencia de resistencia 31 . En Estados Unidos de América, un incremento de 40% en el uso de quinolonas ocasionó que se duplicara la tasa de resistencia hacia ciprofloxacina contra bacilos gramnegativos aislados en Unidades de Cuidados Intensivos.…”
Section: Perspectivas Actualesunclassified